Session » (1221–1247) Pain in Rheumatic Disease Including Fibromyalgia Poster

Date: Monday, October 27, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 1225

Association between Anxiety and Tender Swollen Joint Difference in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1241

Beyond Pain Severity in Psoriatic Arthritis: Pain Catastrophizing Independently Impacts Disease Burden and Quality of Life

10:30AM-12:30PM: Abstract Number: 1243

Broad Cytokine Dysregulation in Fibromyalgia Patients: A Pilot Immune Profiling Study

10:30AM-12:30PM: Abstract Number: 1230

Chronic pain phenotypes in older adults: Identifying patterns of musculoskeletal pain and associated burden

10:30AM-12:30PM: Abstract Number: 1224

Comparative Effectiveness of Duloxetine versus Pregabalin in Fibromyalgia: A Large-Scale, Real-World Study Across 300,000 Patients

10:30AM-12:30PM: Abstract Number: 1235

Demystifying Pain in patients with Lupus: How much is it Lupus and How much is it Other Stuff?

10:30AM-12:30PM: Abstract Number: 1232

Does Social Support Reduce Bodily Pain among African American Women with SLE?: Findings from a Randomized Controlled Trial

10:30AM-12:30PM: Abstract Number: 1245

Efficacy And Safety of Low-dose Naltrexone In Fibromyalgia: An Updated Systematic Review And Meta-Analysis of Randomized Controlled Trials (RCTs)

10:30AM-12:30PM: Abstract Number: 1222

Efficacy of Fasinumab, An Anti-Nerve Growth Factor Monoclonal Antibody, in Managing Chronic Musculoskeletal Pain: A Systematic Review and Meta-Analysis

10:30AM-12:30PM: Abstract Number: 1229

Extent versus impact: Sex-specific burden of chronic pain in older adults

10:30AM-12:30PM: Abstract Number: 1239

JAK inhibition appears to alter clinical and neurobiological markers of nociplastic pain in rheumatoid arthritis: a 7T MRI Brain study

10:30AM-12:30PM: Abstract Number: 1246

Myo Vs. Myo-fascial Injection for Myofascial Trigger Points. Is There Really a Difference? A Randomized Controlled Trial

10:30AM-12:30PM: Abstract Number: 1221

Oxytocin pathway gene BST1 polymorphism rs4273468 genotype GG is negatively associated with Fibromyalgia

10:30AM-12:30PM: Abstract Number: 1244

PACFiND: Co-Designing Principles To Inform Reconfiguration Of Fibromyalgia Care Across Health Systems

10:30AM-12:30PM: Abstract Number: 1223

Pain and Fibromyalgia Across Autoimmune and Inflammatory Diseases in the AMP AIM Cohort

10:30AM-12:30PM: Abstract Number: 1238

Pain Is Associated with An Increased Risk of Frailty in Veterans with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1226

Preliminary Findings in the Validation of the Modified Pain and Symptom Assessment Tool in Juvenile Fibromyalgia Syndrome

10:30AM-12:30PM: Abstract Number: 1247

Relation of Measures of Pain Sensitization to Widespread Pain

10:30AM-12:30PM: Abstract Number: 1242

Relax the Body: Dual-Agent Nighttime Therapy for Fibromyalgia: Symptom Reduction Using Tricyclic Antidepressants and Muscle Relaxants

10:30AM-12:30PM: Abstract Number: 1234

Serum Antibodies Against Glial Fibrillary Acidic Protein in Fibromyalgia: A Proof-of-Concept Study

10:30AM-12:30PM: Abstract Number: 1240

Serum Olink Proteomics Identifies Novel Mediators of Pain in Lupus Nephritis Patients Without Extrarenal Clinical Activity

10:30AM-12:30PM: Abstract Number: 1237

Six Month Clinical Outcomes of a Digital Therapeutic Augmented Virtual Care Clinic for Fibromyalgia Management

10:30AM-12:30PM: Abstract Number: 1233

Synovial Joint Transcriptomic Differences in Individuals with Knee Osteoarthritis and Neuropathic Pain Symptomology

10:30AM-12:30PM: Abstract Number: 1227

The Composition of Circulating Immune Cells is Associated with Nociplastic Pain in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1231

TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, Demonstrates Pain Reduction and Favorable Tolerability in Patients with Fibromyalgia

10:30AM-12:30PM: Abstract Number: 1228

Transcending barriers to pain care in rural America: a pragmatic comparative effectiveness trial of evidence-based, on-demand, digital behavioral treatments for chronic pain

10:30AM-12:30PM: Abstract Number: 1236

Vestibulocortical Stimulation via Caloric Irrigation in Nociplastic Disease: Therapeutic Effects on Pain, Autonomic Functioning & Quality of Life Measures

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].